1. Home
  2. WHF vs SCLX Comparison

WHF vs SCLX Comparison

Compare WHF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$7.02

Market Cap

162.2M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$13.82

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHF
SCLX
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.2M
139.3M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
WHF
SCLX
Price
$7.02
$13.82
Analyst Decision
Sell
Hold
Analyst Count
2
1
Target Price
$7.75
N/A
AVG Volume (30 Days)
235.7K
73.1K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
26.33%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$76,339,000.00
$40,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
$15.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.39
$3.60
52 Week High
$11.31
$34.27

Technical Indicators

Market Signals
Indicator
WHF
SCLX
Relative Strength Index (RSI) 42.50 34.28
Support Level $6.76 $18.34
Resistance Level $7.08 $20.62
Average True Range (ATR) 0.20 1.04
MACD -0.08 -0.46
Stochastic Oscillator 24.07 13.40

Price Performance

Historical Comparison
WHF
SCLX

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: